Genmab AS ADR GMAB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Stocks to Watch: Intel, Deckers, Edwards Lifesciences, Genmab
-
Genmab, AbbVie Say Lymphoma Drug Failed to Meet Primary Endpoint in Phase 3 Trial
-
Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
-
Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
-
AbbVie, Genmab's Lymphoma Treatment Meets Primary Endpoint in Phase 3 Trial
-
AbbVie, Genmab Lymphoma Treatment Shows Improved Progression-Free Survival
-
Months after cancer drug trial, Merus agrees to be bought at 41% premium
Trading Information
- Previous Close Price
- $35.68
- Day Range
- $34.52–35.80
- 52-Week Range
- $23.62–35.91
- Bid/Ask
- $30.00 / $36.00
- Shares Outstanding
- 624.06M
- Market Cap
- $21.56B
- Volume/Avg
- 6M / 2M
Key Statistics
- Price/Earnings (Normalized)
- 20.77
- Price/Sales
- 5.21
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab’s proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab’s leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Large Core
- Total Number of Employees
- 3,119
- Website
- https://www.genmab.com
Competitors
Valuation
|
Metric
|
GMAB
|
4502
|
INCY
|
|---|---|---|---|
Price/Earnings (Normalized) | 20.77 | 48.22 | 13.07 |
Price/Book Value | 3.56 | 1.20 | 3.71 |
Price/Sales | 5.21 | 1.96 | 4.13 |
Price/Cash Flow | 21.20 | 10.96 | 10.41 |
Price/Earnings
GMAB
4502
INCY
Financial Strength
|
Metric
|
GMAB
|
4502
|
INCY
|
|---|---|---|---|
Quick Ratio | 2.44 | 0.54 | 4.31 |
Current Ratio | 2.46 | 1.14 | 4.59 |
Interest Coverage | 3.88 | 0.07 | 791.55 |
Quick Ratio
GMAB
4502
INCY
Profitability
|
Metric
|
GMAB
|
4502
|
INCY
|
|---|---|---|---|
Return on Assets (Normalized) | 11.74% | 5.53% | 26.83% |
Return on Equity (Normalized) | 21.07% | 11.34% | 35.48% |
Return on Invested Capital (Normalized) | 14.75% | 7.74% | 33.21% |
Return on Assets
GMAB
4502
INCY
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|&sG<&K | LOCK|y?TSN | $128B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|q&j$Gp | LOCK|#hX% | $76B | |||
| Moderna Inc
MRNA
| LOCK|s@h@G< | LOCK|gpD | $75B | |||
| argenx SE ADR
ARGX
| LOCK|f^SsRj& | LOCK|!# | $60B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|GgnFbWh | LOCK|Ggr | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|<$dgXl% | LOCK|mf&!% | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|lBbP#ML | LOCK|$>T< | $26B | |||
| BioNTech SE ADR
BNTX
| LOCK|Z%&g!dz | LOCK|p<M | $24B | |||
| Incyte Corp
INCY
| LOCK|sg?&bk | LOCK|$c$ | $24B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|<n@zFj# | LOCK|%<% | $15B |
United States